Loading companies…
MB
MOYOM Biotech
China · Healthtech · Biotech
Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments.
Absorbable materials for aesthetic medicine
MOYOM develops materials used in regenerative aesthetic procedures. Its platform combines calcium hydroxylapatite microspheres with a physically cross-linked gel, designed to provide structural support and controlled biodegradation. Aphranel is the commercial brand built on that research.
The company’s September 2026 announcement reports Chinese Class III medical-device registration and European MDR certification for Aphranel. It says the product has entered more than 700 medical-aesthetics clinics in China since its May 2025 launch, placing the business beyond laboratory development and into clinical distribution.
Funding history
1 round · 0 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Financing round | Undisclosed | Cathay Consumer Co-Creation Fund — Role not disclosed |
Investors
Cathay Consumer Co-Creation FundFinancing roundCoverage
Sep 28, 2026MOYOM Biotech · Financing roundSimilar companies
GMGeneral MedicineAn online healthcare store where people compare care options and upfront prices, book visits and order medications or lab tests.$120M · Series B
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed